Royalty Pharma plc (RPRX)
Royalty Pharma plc reported revenue of $2.38B for the fiscal year ended Dec 31, 2025, up 5.1% from $2.26B the year before. Net income was $770.95M, a net margin of 32.4% (prior year: $858.98M). At the end of that fiscal year the company reported total assets of $19.62B and shareholders' equity of $9.71B.
Revenue
$2.38B
+5.1% vs prior year
Net income
$770.95M
Net margin 32.4%
Diluted EPS
$1.78
USD per share
Total assets
$19.62B
At Dec 31, 2025
Equity
$9.71B
At Dec 31, 2025
Shares outstanding
388M
As of Nov 10, 2020
Explore Royalty Pharma plc's filings
- Revenue by year — annual and quarterly revenue with growth rates
- Income statement & cash flow — profit, margins, EPS and operating cash flow
- Balance sheet — assets, liabilities, equity, cash and debt
- SEC filings — 10-K and 10-Q filings with links to EDGAR
Latest SEC filings
- 10-QFiled Aug 5, 2026
- 10-QFiled May 6, 2026
- 10-KFiled Feb 11, 2026
- 10-QFiled Nov 5, 2025
- 10-QFiled Aug 6, 2025
- 10-QFiled May 8, 2025
Source: SEC EDGAR XBRL company facts for CIK 1802768 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.